Compositions containing botulinum toxin

JP7579046B2Active Publication Date: 2024-11-07MERZ PHARMA GMBH & CO KGAA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2018537506
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-03-02
Filing Date
2017-02-28
Publication Date
2024-11-07
Estimated Expiration
2037-02-28

Smart Images

  • Figure 0007579046000002
    Figure 0007579046000002
  • Figure 0007579046000003
    Figure 0007579046000003
  • Figure 0007579046000001
    Figure 0007579046000001
Patent Text Reader

Abstract

The present invention relates to compositions comprising (a) a botulinum toxin and (b) non-crosslinked hyaluronic acid, and uses of such compositions for the treatment or prevention of dystonia, spasticity, and / or wrinkles. The present invention also relates to methods for cosmetically smoothing or preventing wrinkles, comprising administering a composition of the present invention. [Selection diagram] None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition comprising (a) a botulinum toxin and (b) non-crosslinked hyaluronic acid, and the use of said composition for the treatment or prevention of dystonia, spasticity, and / or wrinkles. The present invention also relates to a method for cosmetically smoothing or preventing wrinkles, comprising administering a composition of the present invention. [Background technology]

[0002] "Botulinum neurotoxins" (BoNT) can be considered a general term referring to a group of several very similar neurotoxic proteins. Naturally occurring botulinum neurotoxins are produced by the anaerobic, spore-forming bacterium Clostridium botulinum and, more rarely, by other Clostridium species (e.g., C. botulinum, C. barati, and C. argentinense). Currently, there are eight different serotypes of the toxin, known as types A, B, C1, C2, D, E, F, and G. Some of these types, e.g., A, B, E, and F, are toxic to humans, while types C, D, and G are more often toxic to, e.g., birds, horses, cattle, and primates.

[0003] The botulinum toxin complex exists in the form of a macromolecular protein complex containing two components, a neurotoxin component that causes the paralytic action and an associated non-toxic bacterial protein component, which can be regarded as a coat protein containing a hemagglutinin protein and a non-hemagglutinin protein. The molecular weight of the botulinum toxin complex varies depending on the botulinum toxin serotypes A, B, C1, C2, D, E, F, and G, and is about 300 kDa to about 900 kDa. With regard to therapeutic applications, it has been reported that the coat protein has no significant function and does not contribute to the neurotoxic properties. The neurotoxin component is expressed as an inactive single-chain precursor (uncleaved polypeptide), with a molecular weight of about 150 kDa for all known botulinum toxin serotypes. This single-chain precursor is activated by proteolytic cleavage to generate a disulfide-linked two-chain protein. The light chain protein of about 50 kDa contains the catalytic domain and acts as a zinc-containing metalloproteinase and as a zinc-endopeptidase. The heavy chain protein of about 100 kDa contains the translocation domain and the receptor binding domain. The heavy chain mediates binding to presynaptic cholinergic nerve terminals, particularly to the presynaptic portion of the motor endplate or neuromuscular junction, and internalization of the toxin into cells.

[0004] With regard to the foregoing, once transported to the neuromuscular junction, the receptor-binding domain of the heavy chain provides cholinergic specificity, allowing the toxin to bind to presynaptic receptors. The neurotoxin then enters the neuron via receptor-mediated endocytosis and resides within the neuron's endocytic vesicles. Upon acidification of the vesicle, the light chain translocates into the cytoplasm and separates. The light chain protein acts as a zinc-endopeptidase and can separate various proteins of the vesicle fusion apparatus, a subsection that prevents exocytosis of the vesicle. In detail, the toxic portion of the light chain can cleave one or more proteins that form the SNARE protein complex (formed by SNAP-25 syntaxin and VAMP), depending on the BoNT serotype. Usually, the SNARE complex fuses with the membrane, thereby allowing the neurotransmitter acetylcholine to leave the cell. The release of the neurotransmitter acetylcholine into the synaptic cleft transmits a nerve impulse to the muscle, thereby signaling the muscle to contract. Formation of the SNARE complex is essentially prevented through protein cleavage, for example by BoNT / A, which stops the release of acetylcholine, thus blocking communication between nerves and muscles and ultimately resulting in paralysis (botulism).

[0005] However, despite this high toxicity, since the early 1980s botulinum toxin has been used as an approved active pharmaceutical ingredient, inter alia, in the treatment of certain movement disorders, such as eyelid spasms (blepharospasm) or torticollis (spastic torticollis). Furthermore, botulinum toxin is used in the field of aesthetic medicine, for example in aesthetic treatments. In addition, the treatment of glabellar lines is considered to have more psychological effects. In particular, this treatment has been reported to reduce symptoms associated with major depressive disorder.

[0006] Botulinum neurotoxins are inherently unstable, especially under alkaline conditions. In addition, they have been reported to be heat-labile. For this reason, commercially available botulinum neurotoxins are often stored as vacuum-dried or freeze-dried materials and often contain additional excipients added to preserve the integrity and potency of the botulinum neurotoxins during storage and any subsequent possible reconstitution.

[0007] For the above medical and cosmetic applications, botulinum neurotoxin must usually be administered approximately every three months. In order to provide a more desirable administration regimen, US2012 / 014532A1 proposes a depot formulation that is said to increase the residence time of botulinum toxin at subcutaneous locations. With reference to the examples, the hyaluronic acid used in the formulation is substantially cross-linked hyaluronic acid prepared from low molecular weight non-cross-linked hyaluronic acid and a cross-linking agent (e.g., 1,4-butanediol diglycidyl ether). However, the sustained release formulation proposed above seems to have room for improvement in terms of its application. In particular, it is considered that the filler in the formulation of US2012 / 014532 may remain at the administration site for a long time.

[0008] It is therefore an object of the present invention to overcome the above-mentioned drawbacks. In particular, it is an object of the present invention to provide an improved botulinum neurotoxin formulation that extends the duration of the botulinum effect. In particular, a formulation should be provided that ensures that no residues from the previous administration are present when the next administration is administered. Furthermore, undesirable side effects should be prevented or at least significantly reduced.

[0009] The objects of the present invention have been unexpectedly solved by a specific composition comprising (a) a botulinum neurotoxin type A and (b) a non-crosslinked hyaluronic acid having a weight average molecular weight of 2.5 MDa to 4.5 MDa, and by a specific administration regimen of said composition.

[0010] The inventors have found that, while conventional botulinum toxin formulations cannot simply increase the dose of botulinum toxin to increase its uptake into cells to achieve the above effects, the compositions of the present invention allow for the application of unexpectedly high amounts of botulinum neurotoxin. This is because a substantial portion of the botulinum toxin is believed to reach the systemic circulation quickly, either via lymphatic drainage or directly via the venous system. By reaching the systemic circulation, botulinum can diffuse to adjacent tissues and cause side effects at the corresponding location. For example, injection of an excessive amount of conventional botulinum toxin formulations into the glabellar crease can cause ptosis. In the present invention, a significantly higher amount of botulinum neurotoxin can be administered without using a depot formulation that remains at the administration site for days, weeks, or months. Summary of the Invention

[0011] The present invention relates to a method for producing a botulinum neurotoxin comprising the steps of: (a) a botulinum neurotoxin; and (b) a non-crosslinked hyaluronic acid, preferably having an average molecular weight of 2.5 MDa to 4.5 MDa and / or an intrinsic viscosity of 2.7 to 3.3 m. 3 The composition comprises non-crosslinked hyaluronic acid in an amount of 0.1 to 1.0 g / kg.

[0012] The present invention further provides compositions of the invention comprising 220-500 units of a botulinum neurotoxin for use in treating dystonia, 500-1000 units of a botulinum neurotoxin for use in treating spasticity, or 40-50 units of a botulinum neurotoxin for use in treating wrinkles.

[0013] Additionally, the present invention provides a method for cosmetically smoothing or preventing wrinkles in a mammal, preferably wrinkles that are the result of extensive mimetic activity, comprising the steps of (i) administering a composition of the present invention, and (ii) repeating the administration after 4 to 9 months.

[0014] Finally, a subject of the invention is the cosmetic use of a composition according to the invention on wrinkles, preferably the result of mimetic activity, in which the composition applied contains 40 to 50 units of botulinum neurotoxin. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 shows the results of the following examples. [Diagram 2] FIG. 1 shows the prolongation effect provided by the composition of the present invention without increasing side effects. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The compositions of the present invention comprise as a component (a) a botulinum neurotoxin.

[0017] In a preferred embodiment, component (a) is a botulinum neurotoxin type B (BoNT / B). Botulinum neurotoxin type B exhibits catalytic behavior towards the cleavage of vesicle-associated membrane protein 2 (VAMP2).

[0018] In an alternative preferred embodiment, component (a) is a botulinum neurotoxin type E (BoNT / E). Botulinum neurotoxin type E also cleaves the 25 kD (kilodalton) synaptosomal associated protein 25 (SNAP-25), but targets a different amino acid sequence within this protein, for example, compared to botulinum neurotoxin type A. Botulinum neurotoxin type E includes eight subtypes BoNT / E1 to BoNT / E8 and may also exist as recombinant botulinum neurotoxins. The sequences and preparation of botulinum neurotoxins type E are disclosed, for example, in WO2014 / 068317. In particular, reference is made to SEQ ID NOs: 1, 2, and 3.

[0019] In a particularly preferred embodiment, the composition of the invention comprises as a component (a) a botulinum neurotoxin type A.

[0020] Preferably, the botulinum neurotoxin type A comprises a neurotoxin component of about 150 kDa, which can be separated into the light (about 50 kDa) and heavy (about 100 kDa) chains described above, and optionally one or more coat proteins (e.g., hemagglutinin or non-hemagglutinin). In a preferred embodiment, the weight molecular weight of the botulinum neurotoxin type A complex can be between 300 kDa and 900 kDa, in particular 300, 600, or 900 kDa. Alternatively, a preferred botulinum neurotoxin type A complex comprises a neurotoxin component and a further protein (e.g., hemagglutinin or non-hemagglutinin protein).

[0021] Botulinum neurotoxin type A is considered to be a highly toxic compound. LD in mice 50 Values ​​range from approximately 30 pg / kg when administered intravenously to 3 ng / kg when inhaled. The dose of botulinum is related to biological activity and is measured in biological units (E) and mouse units (MU) respectively (1 E corresponds to 1 MU). One biological unit (E) corresponds to the amount of toxin injected into the abdomen, which is sufficient to kill 50% of a group of female Swiss Webster mice weighing 18-20 grams.

[0022] As mentioned above, botulinum neurotoxin type A can be obtained from cultures of Clostridium botulinum. The protein can be precipitated from the culture medium and purified by several steps of centrifugation, precipitation, and adsorption. The purified toxin can be stored at -70°C and subsequently thawed without loss of toxin potency. A solution of solid toxin and sterile isotonic saline can be stored in a refrigerator for up to 4 hours without loss of potency. This reconstitution can be done by adding a specific amount of 0.9% saline to a specific amount of botulinum toxin to obtain a specific concentration of botulinum neurotoxin type A per volume (usually measured in units / ml).

[0023] In one embodiment, the invention encompasses isoforms, homologs, orthologs, and paralogs of botulinum toxins that exhibit at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, and up to 60%, up to 70%, up to 80%, up to 90%, up to 100% sequence identity to wild-type botulinum toxin A. Sequence identity can be calculated by any algorithm suitable for obtaining reliable results, for example, the FASTA algorithm (WR Pearson & DJ Lipman PNAS (1988) 85:2444-2448). Sequence identity can be calculated by comparing two polypeptides or two domains (e.g., two LC domains or fragments thereof). Modified recombinant botulinum toxins are also within the scope of the invention. However, the present invention also refers to chemically modified botulinum toxins, such as those chemically modified by pegylation, glycosylation, sulfation, phosphorylation, or any other modification, especially modification of one or more surface or solvent exposed amino acids. The modified recombinant isoforms, homologs, orthologs, paralogs, and variants suitable for use in the present invention are biologically active, i.e., capable of translocating to neurons and cleaving proteins of the SNARE complex (e.g., SNAP25) to exert their muscle paralytic effects.

[0024] The composition of the present invention further comprises hyaluronic acid as component (b). Hyaluronic acid is a glycosaminoglycan that can be represented by the following structural formula:

[0025] [ka]

[0026] Hyaluronan can therefore be considered as a disaccharide polymer composed of two glucose derivatives, D-glucuronic acid and D-acetylglucosamine, in which the glucuronic acid is linked to an N-acetylglucosamine via a β(1→3) glycosidic bond, and the N-acetylglucosamine is linked to an adjacent glucuronic acid via a β(1→4) glycosidic bond.

[0027] The inventors have found that the composition of the present invention should contain a specific grade of hyaluronic acid. The hyaluronic acid used in the present invention has a fairly high molecular weight, but this high molecular weight is not achieved by cross-linking, but by linear chains of different lengths.

[0028] Generally, the hyaluronic acid used in the present invention as component (b) is non-crosslinked hyaluronic acid. In a preferred embodiment, the average molecular weight of the hyaluronic acid is 2.5 MDa to 4.5 MDa, preferably 2.7 to 4.2 MDa, more preferably 3.0 to 4.0 MDa, and especially 3.3 to 3.8 MDa.

[0029] The average molecular weight of hyaluronic acid was calculated from the intrinsic viscosity of the given compound, and therefore may also be called the "viscosity average molecular weight."

[0030] The intrinsic viscosity of hyaluronic acid was measured at 20°C using an Ubbelohde capillary viscometer and water as the solvent according to Ph.Eur.6.0, 2.2.9. The average molecular weight M of each was calculated according to the Mark-Howink relationship [η] = KM a where η is the intrinsic viscosity, log(K) is the intercept, and a is the slope. Preferably, a can be set to 0.7 for non-crosslinked hyaluronic acid.

[0031] In a preferred embodiment, the hyaluronic acid (b) can be characterized by its intrinsic viscosity (instead of or in addition to the molecular weights mentioned above). Preferably, the intrinsic viscosity is between 2.7 and 3.3 m 3 / kg, more preferably 2.80 to 3.20 m3 / kg, and even more preferably 2.90 to 3.15 m 3 / kg, especially about 3.09m 3 / kg. The viscosity is determined as described above.

[0032] It should be noted that the term "non-crosslinked hyaluronic acid" in the present invention includes all pharma- ceutically acceptable salts, hydrates, and / or solvates thereof. Preferably, non-crosslinked hyaluronic acid is in the form of a sodium salt.

[0033] In a preferred embodiment of the present invention, the polydispersity index of the non-crosslinked hyaluronic acid may be from 1.0 to 5.0, preferably from 1.1 to 4.0, more preferably from 1.2 to 3.5, even more preferably from 1.3 to 3.0, particularly from 1.4 to 2.5, and especially from 1.5 to 2.0.

[0034] In terms of chemistry, dispersity can be viewed as a dimension of heterogeneity in the size of molecules or particles. In a homogeneous collection, the objects have the same size, shape, or mass. The polydispersity index (PDI) or simply the dispersion index D is a measure of the distribution of molecular masses in a given polymer sample and is calculated according to the following formula: PDI=M w / M n (In the formula, Mw is the weight average molecular weight, M n is the number average molecular weight) Mw and M n Both can be determined by gel permeation chromatography (GPC).

[0035] In a preferred embodiment, the composition of the present invention may contain 2 to 4 units, preferably 2.2 to 3.8 units, more preferably 2.4 to 3.6 units of a botulinum neurotoxin, preferably a botulinum neurotoxin type A, per milligram of non-crosslinked hyaluronic acid.

[0036] In an alternative preferred embodiment, the composition of the present invention may contain 20 to 40 units, preferably 22 to 38 units, more preferably 24 to 36 units of a botulinum neurotoxin, preferably a botulinum neurotoxin type A, per milligram of non-crosslinked hyaluronic acid.

[0037] The compositions of the present invention can include a variety of other pharma- ceutically acceptable substances, such as salts, radical scavengers, neurotoxin stabilizers, crystallization inhibitors, sugars, amino acids, vitamins, anesthetics, surfactants, osmolality regulators, and the like. As used herein, the term "pharma-ceutically acceptable" refers to a compound or substance that is suitable for contact with mammalian, particularly human, tissue. As used herein, the term "comprise" is intended to encompass both the open-ended term "include" and the closed term "consist (of)."

[0038] In one embodiment, the composition of the present invention preferably comprises c) Salt d) Neurotoxin stabilizers e) Crystallization inhibitors f) buffers and / or g) Radical Scavenger Includes.

[0039] The salt (c) can be any physiologically acceptable salt, preferably a sodium salt, more preferably sodium chloride.

[0040] A neurotoxin stabilizer (d) can be considered as a compound that stabilizes the botulinum neurotoxin, preferably botulinum neurotoxin type A, protein and prevents the degradation of said protein. Examples include proteins such as human serum albumin (HAS) and gelatin, with HAS being preferred.

[0041] In an alternative preferred embodiment, the compositions of the invention do not contain any neurotoxin stabilizers, and preferably do not contain human serum albumin (HAS).

[0042] Crystallization inhibitors (e) are substances that prevent the crystallization of the neurotoxin, for example during the lyophilization step. Examples of crystallization inhibitors are sugars, such as glucose, fructose, galactose, trehalose, sucrose, and maltose. Glucose, fructose, and sucrose are preferred, especially sucrose.

[0043] Buffer (f) is a substance used to provide a specific pH value to achieve painless application (e.g. injection) when the composition is in the form of a solution, preferably an aqueous solution. Preferably, when the composition is in the form of an aqueous solution, the buffer provides a pH value between 6.1 and 7.6, preferably between 6.2 and 7.2, more preferably between 6.3 and 7.1, especially between 6.5 and 7.0. The buffer can be, for example, a phosphate buffer, a citrate-phosphate buffer, a lactate buffer, an acetate buffer, etc.

[0044] Compounds that prevent or slow the degradation of botulinum toxin can be considered radical scavengers (g). Examples of radical scavengers include polyols (e.g., glycerin) and sugar alcohols (e.g., mannitol, inositol, lactitol, isomalt, xylitol, erythritol, and sorbitol).

[0045] In a preferred embodiment, the composition of the present invention does not include mannitol.

[0046] In one embodiment, the composition of the present invention preferably comprises a) 20 to 40 units of a botulinum neurotoxin, preferably type A botulinum neurotoxin b) 2.5 to 9 mg of non-crosslinked hyaluronic acid c) 3.6 to 20 mg of a salt, preferably sodium chloride d) 0-1.5 mg or 0.2-1.5 mg of a neurotoxin stabilizer, preferably human serum albumin. e) 0.4 to 0.94 mg of a crystallization inhibitor f) 0.3 to 0.6 mg of a buffer solution, preferably a phosphate buffer solution g) 20-40 mg of a radical scavenger Contains:

[0047] The above-mentioned composition can preferably be in the form of a lyophilisate, so that the composition can be stored without losing the effectiveness of the botulinum neurotoxin, preferably botulinum neurotoxin type A. A composition comprising a lyophilised botulinum neurotoxin, preferably botulinum neurotoxin type A, can be obtained by reconstituting the lyophilisate with sterile saline. The reconstitution is preferably carried out with 0.9% saline, preferably in a volume of 1 ml. The concentration of the aqueous composition can preferably be in the following ranges: a) 20 to 40 units of a botulinum neurotoxin per ml, preferably type A botulinum neurotoxin b) 0.25-0.9% w / v hyaluronic acid c) 0.36 to 2.0% w / v of a salt, preferably sodium chloride d) 0-0.15% w / v or 0.02-0.15% w / v of a neurotoxin stabilizer, preferably human serum albumin e) 0.04 to 0.094% w / v crystallization inhibitor f) 0.03 to 0.06% w / v buffer, preferably phosphate buffer g) 2.0-4.0% w / v radical scavenger

[0048] In an alternative embodiment, the composition of the present invention preferably comprises a) 200 to 400 units of a botulinum neurotoxin, preferably type A botulinum neurotoxin b) 2.5 to 9 mg of non-crosslinked hyaluronic acid c) 3.6 to 20 mg of a salt, preferably sodium chloride d) 0-15 mg or 0.2-1.5 mg of a neurotoxin stabilizer, preferably human serum albumin. e) 4 to 9.4 mg of a crystallization inhibitor f) 0.3 to 0.6 mg of a buffer solution, preferably a phosphate buffer solution g) 200-400 mg of a radical scavenger It may contain:

[0049] The above alternative compositions may preferably be in the form of a lyophilisate, so that the composition can be stored without losing the potency of the botulinum neurotoxin, preferably botulinum neurotoxin type A. A composition comprising a botulinum neurotoxin, preferably botulinum neurotoxin type A, may be obtained by reconstituting the lyophilisate with sterile saline. The reconstitution is preferably performed with 0.9% saline, preferably in a volume of 1 ml. The concentration of the aqueous composition may preferably be in the following ranges: a) 200 to 400 units of a botulinum neurotoxin per ml, preferably type A botulinum neurotoxin b) 0.25-0.9% w / v hyaluronic acid c) 0.36 to 2.0% w / v of a salt, preferably sodium chloride d) 0-1.5% w / v or 0.2-1.5% w / v of a neurotoxin stabilizer, preferably human serum albumin e) 0.4 to 0.94% w / v crystallization inhibitor f) 0.03 to 0.06% w / v buffer, preferably phosphate buffer g) 20-40% w / v radical scavenger

[0050] In a preferred embodiment, the composition of the invention may comprise two sub-compositions. The first sub-composition may preferably comprise components a), d), e) and g) in the form of a lyophilisate that is reconstituted with 0.9% sterile saline when used. In an alternative preferred embodiment, the first sub-composition in the form of a lyophilisate does not contain human serum albumin (HSA). The second sub-composition may preferably comprise an aqueous solution of components b) and f). Both sub-compositions may preferably be combined to obtain the actual composition before application.

[0051] In a preferred embodiment, the composition of the invention can be present as a ready-to-use composition, i.e. the composition of the invention can be present in a form that can be administered directly to a patient. In a preferred embodiment, the composition can be present in the form of a pre-filled glass or syringe, which can preferably be stored at a temperature of 0-15°C, more preferably 2-10°C.

[0052] In the form of a reconstituted solution, the compositions of the invention may preferably have a dynamic viscosity of 1.5-4 Pa·s, preferably 1.7-3.8 Pa·s, more preferably 2.0-3.0 Pa·s, as determined using an oscillation frequency of 1 Hz at 25° C. This solution viscosity allows for application by injection, for example through a 25-32 gauge needle.

[0053] The complex viscosity was determined using an Anton Paar MCR 302 rheometer. The oscillation frequency varied from 10 Hz to 0.1 Hz. At 1 Hz and 25°C, complex viscosities of 2.31 to 2.45 Pa*s, G' of 8.9485 to 9.5135, and tan(δ) of 1.279 to 1.282 were measured.

[0054] Furthermore, when in the form of a reconstituted solution, the compositions of the invention may preferably have an osmolality of 200 to 400 mOsmoles per liter, preferably 250 to 370 mOsmoles per liter, especially 270 to 325 mOsmoles per liter. Preferably, the osmolality may be determined according to Ph.Eur 6.0, section 2.2.35.

[0055] A further subject of the invention is a composition according to the invention for use in the treatment of dystonia, in which preferably 200 to 500 units of botulinum neurotoxin, preferably type A botulinum neurotoxin, are administered. More preferably, 220 to 480, 240 to 460, 260 to 440, 280 to 420, 300 to 400, 320 to 380 or 340 to 380 units or any combination of these, for example 240 to 380 units, can be used.

[0056] Dystonia describes a pathological condition characterized by a dysfunction of muscle tone. Dystonia is considered an extrapyramidal hyperkinesis. Dystonia can result in sustained, involuntary contractions of (skeletal) muscles. This dysfunction is expressed in extreme tension and misalignment of the body. Dystonia can occur as an independent disease pattern (primary dystonia), for example due to a genetic defect, or in association with other diseases (secondary dystonia), for example Parkinson's disease, or as a result of a stroke. Depending on the grade of spread, dystonia can be classified into three types: Focal dystonia (affecting only one body part) Segmental dystonia (affecting two or more body parts) Generalized dystonia (affects the entire body)

[0057] Examples of focal dystonias include pharyngeal (phonation dystonia) or cervical dystonia (head / neck misalignment) (alternatively cervical dystonia can also be considered segmental dystonia), blepharospasm (uncontrolled eyelid blinking), oromandibular dystonia (disorders of the oral area and / or chewing), and spasmodic dystonia (disorders of the vocal cords). An example of a generalized dystonia is Segawa's disease, which is characterized by abnormal leg position.

[0058] In one embodiment, the composition of the invention for use in the treatment of dystonia is administered parenterally, preferably in the form of an injection, preferably in or near the affected area, preferably subcutaneously or intramuscularly, in particular intramuscularly.

[0059] A further subject of the invention is a composition according to the invention for use in the treatment of spasticity, in which preferably 500 to 1000 units of a botulinum neurotoxin, preferably type A botulinum neurotoxin, are administered. More preferably, 550 to 950, 600 to 900, 650 to 850 or 700 to 800 units or any combination of these, for example 600 to 850 units, can be used.

[0060] Spasticity can be described as an increase in internal tension of (skeletal) muscles. The cause of spasticity is damage to the areas of the central nervous system responsible for movement, namely the brain and spinal cord, specifically the pyramidal tracts of the first motor neurons. The most common reason for spasticity is hypoxic damage to the areas of the brain involved in movement, due to cerebral infarction. Monospasticity is spastic paralysis of one muscle or one limb. Examples of muscles that can be spastic paralyzed are flexor carpi radialis, flexor carpi ulnaris, flexor digitorum superficialis, flexor digitorum profundus, brachioradialis, biceps brachii, pronator quadratus, pronator teres, flexor pollicis longus, flexor pollicis brevis, and opponens pollicis. Symmetric spasticity is characterized by paralysis of both legs. Unilateral spasticity describes paralysis of one limb or half of the face (hemifacial spasm). Finally, tetraspasticity involves spastic paralysis of all four limbs and may also affect the muscles of the neck and trunk.

[0061] In one embodiment, the composition of the invention for use in the treatment of spasticity is administered parenterally, preferably in the form of an injection, which can preferably be made in or near the affected area, preferably subcutaneously or intramuscularly, in particular intramuscularly.

[0062] A further subject of the invention is a composition according to the invention for use in the treatment of wrinkles, in which preferably 40-55 units of botulinum neurotoxin, preferably type A botulinum neurotoxin, are administered. More preferably, 42-52, 43-49, 44-48, or 45-47 units, or any combination thereof, for example 43-50 units, can be used. The treatment of wrinkles with botulinum toxin can have psychological effects. In particular, it has been reported that depressed individuals experience a reduction in depressed mood after their wrinkles, especially glabellar wrinkles, are treated by injection of botulinum toxin.

[0063] In one embodiment, the compositions of the invention for use in the treatment of wrinkles are administered parenterally, preferably in the form of an injection, which can be preferably administered in or near the corresponding wrinkle, preferably the glabellar wrinkle, and preferably subcutaneously.

[0064] A further subject of the present invention is a composition according to the invention for use in the treatment of diseases or conditions associated with overactive cholinergic innervation in muscles or exocrine glands, in which from 20 to 1500 units, preferably from 100 to 800 units of a botulinum neurotoxin, preferably a botulinum neurotoxin type A, are administered.

[0065] The term "hyperactive cholinergic innervation" as used herein refers to synapses characterized by an abnormally high amount of acetylcholine released into the synaptic cleft. "Abnormally high" refers, for example, to an increase of up to 25%, up to 50% or more over baseline activity, which can be obtained, for example, by comparison with the release in synapses of the same type but not in an overactive state (muscle dystonia can indicate an overactive state). "Up to 25%" means, for example, about 1% to about 25%. Methods for carrying out the required measurements are known in the art.

[0066] Exemplary diseases or conditions associated with overactive cholinergic innervation of muscles or exocrine glands include, for example, Frey's syndrome, crocodile tears syndrome, axillary hyperhidrosis, plantar hyperhidrosis, head and neck hyperhidrosis, generalized hyperhidrosis, runny nose, Parkinson's disease, amyotrophic lateral sclerosis, hypersalivation, sialorrhea, sialorrhea, spastic conditions and palatal myoclonus, myoclonus, myokymia, rigidity, benign muscle spasms, hereditary chin tremor, paradoxical jaw muscle activity, unilateral masseter muscle spasms, hypertrophic branchial myopathy, masseter hypertrophy, anterior tibial hypertrophy, nystagmus, oscillopsia, supranuclear gaze palsy, persistent These include partial epilepsy, surgical planning for spasmodic torticollis, abductor vocal cord paralysis, refractory variant dysphonia, upper esophageal sphincter insufficiency, vocal fold granuloma, stuttering, Gilles de la Tourette syndrome, middle ear myoclonus, protective pharyngeal closure, post-pharyngeal resection speech disorder, protective ptosis, entropion, sphincter of Oddi insufficiency, pseudoachalasia, nonachalasia esophageal motility disorder, vaginismus, post-operative motor inhibition, tremor, bladder dysfunction, hemifacial spasm, reinnervation dyskinesia, rigid body syndrome, tetanus, prostatic hyperplasia, bariatric procedures, childhood cerebral palsy, achalasia, and anal fissure.

[0067] In one embodiment, the composition of the invention for use in treating diseases or conditions associated with overactive cholinergic innervation in muscles or exocrine glands can be administered preferably parenterally, preferably in the form of an injection, which can be preferably given in or near the corresponding body site, and preferably intramuscularly or subcutaneously.

[0068] In a preferred embodiment, the composition of the present invention remains at the site of administration for up to 24 hours after administration. This means that once administered, the composition is cleared, degraded and / or metabolized from the injection site within 24 hours. Furthermore, it is desirable for the composition of the present invention to remain at the site of administration for at least 10 hours after administration, i.e., in a preferred embodiment, the composition of the present invention is present at the site of administration for 10 to 24 hours, preferably 11 to 22 hours, more preferably 12 to 20 hours after administration.

[0069] In a preferred embodiment of the composition of the present invention, the botulinum neurotoxin type A is released within 12 hours after administration. The release of the botulinum neurotoxin type A from the composition of the present invention is at least 50% within 12 hours, i.e. 50% to 100%, preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, especially at least 90%. The release of the botulinum neurotoxin type A from the composition within the above period ensures that the botulinum neurotoxin type A is available to the corresponding neuronal cells without significant loss of efficacy due to systemic elimination of the toxin. This means that, unlike the teaching of US2012 / 0141532, the composition of the present invention is not a depot formulation that remains at the site of administration for more than several weeks. Instead, the present invention is based on the concept that an extended effect of the botulinum neurotoxin is obtained even if the botulinum neurotoxin is released within a significantly shorter period of time compared to US2012 / 0141532.

[0070] In contrast to the present invention, currently available non-sustained release compositions of botulinum are typically applied every 6 to 12 weeks. Such frequent application of botulinum toxin is generally undesirable, for example, such frequent application has been reported to produce resistance. For example, secondary non-responders have been reported to result from the presence of neutralizing antibodies.

[0071] Therefore, in another preferred embodiment, the composition of the present invention is administered in a more advantageous dosing regimen. The composition of the present invention can be preferably administered every 4-9 months, preferably every 5-7 months, more preferably about every 6 months. However, compared to the above-mentioned state of the art, the composition of the present invention is not based on a depot formulation in which the botulinum neurotoxin is released in a sustained manner. Instead, as mentioned above, the botulinum is preferably released from the composition within 12 hours and absorbed by the neuronal cells. Furthermore, as also mentioned above, after about 24 hours, the remainder of the composition of the present invention begins to degrade or be eliminated systemically, and within a few days, no part of the composition of the present invention remains at the site of administration.

[0072] A further subject of the present invention is a method for cosmetically smoothing or preventing wrinkles in a mammal, preferably wrinkles which are the result of extensive mimetic activity, comprising the steps of: (i) administering a composition of the invention; (ii) repeating the administration after 4 to 9 months; and The method includes:

[0073] Wrinkles may be considered as folds, ridges, or creases in the skin. Wrinkles, which are the result of extensive mimetic activity, may refer to substantially any wrinkle visible on the face of a corresponding mammal, preferably a human. Examples of wrinkles include furrows, frown lines, crow's feet, cheek seams, jaw lines, perioral wrinkles, cheek folds, marionette lines, lip lines, forehead wrinkles, frown lines, bunny lines, nasolabial folds, under-eye wrinkles, and chin folds. Step (i) of administering the composition of the invention may preferably comprise administering the composition of the invention by injection. The injection may preferably be performed with a needle, preferably with a needle size of 27-35 gauge, preferably 30-33 gauge. The composition of the invention may preferably be injected in or near the site of the corresponding wrinkle. The injection may be subcutaneous or intramuscular, especially subcutaneous. Preferably, the compositions of the present invention are administered to the areas of frown lines, horizontal lines, crow's feet, perioral folds, mental ceases, chin wrinkles, and / or sagging platysma muscles.

[0074] Botulinum toxin can be administered on the same day as treatment or on the next day after treatment.For example, the first fraction of the dose can be administered during the first treatment session.The first fraction is preferably a suboptimal fraction, i.e., a fraction that does not completely remove wrinkles or skin lines.The remaining fractions of the total dose can be administered during one or more treatment sessions.

[0075] Repeating the administration after 4-9 months, step (ii) preferably comprises administering the composition of the invention using the same conditions / devices as described above. By repeating the administration of the composition of the invention, additional doses of botulinum become available to the cells, and the corresponding skin preferably remains cosmetically smooth. In alternative embodiments, the administration is repeated after 5-7 months or 5-8 months.

[0076] In a preferred embodiment of the method of the present invention, the composition of the present invention administered contains 40-55 units of botulinum neurotoxin, preferably botulinum neurotoxin type A. More preferably, 42-52, 43-49, 44-48, or 45-47 units, or any combination thereof, for example, 43-50 units, can be used. A method for smoothing or preventing wrinkles common in the art includes administering about 20 units of neurotoxin. It has been reported that the use of compositions containing high doses of neurotoxin significantly increases the risk of undesirable side effects such as ptosis (e.g., ptosis). However, in the method of the present invention, such negative side effects may not be observed, and a high dose of neurotoxin becomes available to the cells, thereby resulting in extended efficacy. Similar to the above explanation, in the cosmetic method of the present invention, botulinum neurotoxin A is preferably released from the composition of the present invention within 12 hours.

[0077] A further subject of the invention is the cosmetic use of a composition according to the invention for smoothing or preventing wrinkles, preferably wrinkles which are the result of mimetic activity, in which the composition according to the invention to be applied comprises 40 to 55 units of a botulinum neurotoxin, preferably a type A neurotoxin. More preferably, 42 to 52, 43 to 49, 44 to 48 or 45 to 47 units or any combination of these, for example 43 to 50 units, can be used.

[0078] As shown above, the prior art compositions are reported to contain about 20 units of botulinum neurotoxin when used cosmetically to smooth or prevent wrinkles. The high amount of 40-55 units of botulinum neurotoxin, preferably type A neurotoxin, contained in the applied composition ensures that more units of botulinum are available to the corresponding cells, and the use of the present composition to smooth or prevent wrinkles ensures the prolongation of the effect of the neurotoxin applied in the present composition. The invention can be illustrated by the following examples. EXAMPLES

[0079] 1. Preparation of the Composition Example 1 Two subunits of the composition were prepared.

[0080] A lyophilizate containing 1:50 subunit units of botulinum neurotoxin type A, 25 mg human serum albumin (HAS), and 1.18 mg sucrose was reconstituted with 1 ml of 0.9% saline.

[0081] Subunit 2: 1 ml water 、1 A solution containing 4 mg of non-crosslinked hyaluronic acid, 34 mg of mannitol, 3.0 mg of glycerin, and 0.6 mg of phosphate buffer was prepared.

[0082] The subunits were mixed such that 1 ml of the resulting aqueous composition contained, respectively: Botulinum neurotoxin type A 25 units Non-crosslinked hyaluronic acid 7mg Human serum albumin (HAS) 0.125mg Sucrose 0.59mg Mannitol 17.0mg Glycerin 1.5mg Phosphate buffer solution 0.3mg Sodium chloride 4.5mg

[0083] Reference Example A reference composition is obtained as follows: a lyophilisate containing 50 units of botulinum neurotoxin type A, 25 mg of human serum albumin (HAS) and 1.18 mg of sucrose was reconstituted with 1 ml of 0.9% saline.

[0084] The resulting aqueous compositions therefore each contained: Botulinum neurotoxin type A 50 units Human serum albumin (HAS) 0.25mg Sucrose 1.18mg Sodium chloride 0.9mg

[0085] 2. Comparison of efficacy 2.1 Two groups of 10 mice were injected into the right gastrocnemius muscle with either 0.8 ml of the composition of the reference example or 1.6 ml of the composition of Example 1 (both containing 40 units of botulinum neurotoxin type A). No deaths were observed in either group. Signs of minor systemic toxicity occurred in both groups at similar severity on days 2-10.

[0086] As can be seen from Figure 1, the maximum score was 4 (DAS score), which indicates complete paralysis of the hind limbs. The time from onset of paralysis to maximum paralysis was 1 day. The duration of paralysis to reach the EC50 level (DAS score 2) in mice was about 12 days for the reference composition and about 30 days for the composition of the present invention. Thus, the composition of the present invention provides an unexpected prolonged effect without increasing side effects.

[0087] 2.2 The comparison according to item 2.1 above was repeated, and mice treated with the composition of the present invention were injected with 2.5 ml of the composition of Example 1, i.e., 62.5 units of botulinum neurotoxin type A. No deaths were observed in either group. Signs of minor systemic toxicity occurred in both groups at the same level on days 2-10.

[0088] FIG. 2 shows the prolongation effect provided by the composition of the present invention without an increase in side effects.

Claims

1. a) a botulinum neurotoxin, and b) Non-crosslinked hyaluronic acid having an average molecular weight of 2.5 MDa to 4.5 MDa and having a dynamic viscosity of 1.5 to 4 Pa·s when determined using an oscillation frequency of 1 Hz at 25° C.

2. The composition of claim 1 , wherein the botulinum neurotoxin is a type A botulinum neurotoxin.

3. The composition according to claim 1 or 2, wherein the polydispersity index of the non-crosslinked hyaluronic acid is from 1.1 to 4.

0.

4. The composition according to any one of claims 1 to 3, comprising 2 to 4 units of botulinum neurotoxin or 20 to 40 units of botulinum neurotoxin per milligram of non-crosslinked hyaluronic acid.

5. c) salt, d) optionally a neurotoxin stabilizer; e) crystallization inhibitors; f) a buffer solution, and / or g) Radical Scavenger The composition of any one of claims 1 to 4, further comprising:

6. 6. A composition according to any one of claims 1 to 5 for use in the treatment or prevention of dystonia, wherein 200 to 500 units of botulinum neurotoxin are administered.

7. A composition according to any one of claims 1 to 5 for use in the treatment or prevention of spasticity, wherein 500 to 1000 units of the botulinum neurotoxin are administered.

8. A composition according to any one of claims 1 to 5 for use in the prevention or treatment of wrinkles, wherein 40 to 50 units of botulinum neurotoxin are administered.

9. A composition according to any one of claims 1 to 8, which remains at the site of application for up to 24 hours after application.

10. The composition of any one of claims 1 to 9, wherein the botulinum neurotoxin is released within 12 hours.

11. The composition of any one of claims 1 to 10, administered every 4 to 9 months.

12. 6. The composition of any one of claims 1 to 5, administered every 4 to 9 months to cosmetically smooth or prevent mammalian wrinkles.

13. The composition of claim 12, comprising 40 to 50 units of botulinum neurotoxin.

14. A composition according to any one of claims 1 to 5, comprising 40 to 50 units of botulinum neurotoxin for smoothing or preventing wrinkles.

Citation Information

Patent Citations

  • Dermal filler

    US20090155314A1

  • Botulinum Toxin Formulation

    US20120141532A1